DOI QR코드

DOI QR Code

Prognostic Significance of Circulating Tumor Cells in Small-Cell Lung Cancer Patients: a Meta-analysis

  • Zhang, Jiao (Department of Interventional Therapy, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital) ;
  • Wang, Hai-Tao (Department of Interventional Therapy, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital) ;
  • Li, Bao-Guo (Department of Interventional Therapy, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital)
  • Published : 2014.10.23

Abstract

Circulating tumor cells (CTCs) are believed to be particularly important and a reliable marker of malignancy. However, the prognostic significance of CTCs detected in patients with small cell lung cancer (SCLC) is still unclear. We therefore aimed to assess the prognostic relevance of CTCs using a meta-analysis. We searched PubMed for relevant studies and statistical analyses were conducted to calculate the hazard ratio (HR) and 95% confidence intervals (CIs) using fixed or random-effect models according to the heterogeneity of included studies. A total of 7 papers covering 440 SCLC patients were combined in the final analysis. The meta-analysis revealed that CTCs were significantly associated with shorter overall survival (HR=1.9; 95%CI: 1.19-3.04; Z=2.67; P<0.0001) and progression-free survival (HR=2.6; 95%CI: 1.9-3.54; Z=6.04; P<0.0001). The results thus suggest that the presence of CTCs indicates a poor prognosis in patients with SCLC. Further well-designed prospective studies are required to explore the clinical applications of CTCs in SCLC.

Keywords

References

  1. Albain KS, Crowley JJ, LeBlanc M, et al (1990). Determinants of improved outcome in small-cell lung cancer: an analysis of the 2, 580-patient Southwest Oncology Group data base. J Clin Oncol, 8, 1563-74.
  2. Alix-Panabieres C, Riethdorf S, Pantel K (2008). Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res, 14, 5013-21. https://doi.org/10.1158/1078-0432.CCR-07-5125
  3. American Cancer Society (2009). Cancer facts and figures 2009. Atlanta: American Cancer Society.
  4. Cohen SJ, Punt CJA, Iannotti N, et al (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol, 26, 3213-21. https://doi.org/10.1200/JCO.2007.15.8923
  5. Cristofanilli M, Budd GT, Ellis MJ, et al (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med, 351, 781-91. https://doi.org/10.1056/NEJMoa040766
  6. de Bono JS, Scher HI, Montgomery RB, et al (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res, 14, 6302-9. https://doi.org/10.1158/1078-0432.CCR-08-0872
  7. Foster NR, Mandrekar SJ, Schild SE, et al (2009). Prognostic factors differ by tumor stage for small cell lung cancer. Cancer, 115, 2721-31. https://doi.org/10.1002/cncr.24314
  8. Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  9. Hiltermann TJN, Pore MM, Van den Berg A, et al (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol, 23, 2937-42. https://doi.org/10.1093/annonc/mds138
  10. Horner MJ, Ries LAG, Krapcho M (2009). SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Based on November 2008 SEER submission data, posted to the SEER website.
  11. Hou JM, Krebs MG, Lancashire L, et al (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol, 30, 525-32. https://doi.org/10.1200/JCO.2010.33.3716
  12. Hou JM, Greystoke A, Lancashire L, et al (2009). Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol, 175, 808-16. https://doi.org/10.2353/ajpath.2009.090078
  13. Huang J, Wang K, Xu J, et al (2013). Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PloS one, 8, 78070. https://doi.org/10.1371/journal.pone.0078070
  14. Igawa S, Gohda K, Fukui T, et al (2014). Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett, 7, 1469.
  15. Kato Y, Ferguson TB, Bennett DE et al (1969). Oat cell carcinoma of the lung. A review of 138 cases. Cancer, 23, 517-24. https://doi.org/10.1002/1097-0142(196903)23:3<517::AID-CNCR2820230301>3.0.CO;2-L
  16. Krebs MG, Sloane R, Priest L, et al (2011). Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol, 29, 1556-63. https://doi.org/10.1200/JCO.2010.28.7045
  17. Ma XL, Li YY, Zhang J, et al (2014). Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 6015. https://doi.org/10.7314/APJCP.2014.15.15.6015
  18. Ma XL, Xiao ZL, Liu L, et al (2012). Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pac J Cancer Prev, 13, 1137-44. https://doi.org/10.7314/APJCP.2012.13.4.1137
  19. Naito T, Tanaka F, Ono A, et al (2012). Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol, 7, 512-9. https://doi.org/10.1097/JTO.0b013e31823f125d
  20. Normanno N, Rossi A, Morabito A, et al (2014). Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer, 85, 314-9. https://doi.org/10.1016/j.lungcan.2014.05.002
  21. Oshita F, Sekiyama A, Suzuki R, et al (2003). Detection of occult tumor cells in peripheral blood from patients with small cell lung cancer by promoter methylation and silencing of the retinoic acid receptor-beta. Oncol Rep, 10, 105-8.
  22. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  23. Rolle A, Gunzel R, Pachmann U et al (2005). Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC (R) is a predictor for relapse: A preliminary report. World J Surg Oncol, 3, 18. https://doi.org/10.1186/1477-7819-3-18
  24. Shi W L, Li J, Du Y J, et al (2013). CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients. Med Oncol, 30, 1-8.
  25. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. Ca-Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
  26. Takada M, Fukuoka M, Kawahara M et al (2002). Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol, 20, 3054-60. https://doi.org/10.1200/JCO.2002.12.071
  27. Tanaka F, Yoneda K, Kondo N, et al (2009). Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res, 15, 6980-6. https://doi.org/10.1158/1078-0432.CCR-09-1095
  28. Turker I, Uyeturk U, Sonmez OU, et al (2013). Detection of circulating tumor cells in breast cancer patients: prognostic predictive role. Asian Pac J Cancer Prev, 14, 1601-7. https://doi.org/10.7314/APJCP.2013.14.3.1601
  29. Turrisi A T, Kim K, Blum R, et al (1999). Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. New Engl J Med, 340, 265-71. https://doi.org/10.1056/NEJM199901283400403
  30. Wu C, Hao H, Li L, et al (2009). Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol, 4, 30-6. https://doi.org/10.1097/JTO.0b013e3181914125
  31. Yip D, Harper PG (2000). Predictive and prognostic factors in small cell lung cancer: current status. Lung cancer, 28, 173-85. https://doi.org/10.1016/S0169-5002(00)00105-7

Cited by

  1. Epidemiology Characteristics and Trends of Lung Cancer Incidence in Iran vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.557
  2. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma vol.17, pp.1, 2019, https://doi.org/10.1186/s12967-019-1779-5